Virus therapy takes on tough melanoma in early trial
NCT ID NCT07086105
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-stage study tests a new treatment called Adze1.C, a virus designed to infect and kill cancer cells while also boosting the immune system. It is for adults with advanced melanoma that has not responded to standard therapies. The main goals are to check the treatment's safety, find the best dose, and see how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
-
The Queen Elizabeth Hospital
RECRUITINGAdelaide, South Australia, 5011, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma